The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have early stage triple-negative breast cancer (TNBC) without mutations in the BRCA1 or BRCA2 gene and who have cancer remaining after neoadjuvant treatment and surgery. This study will test an experimental drug named sacituzumab govitecan in combination with pembrolizumab compared to pembrolizumab with or without capecitabine. The purpose of this study is to see if this combination can delay the return of disease and improve other outcomes in participants with high-risk early stage TNBC compared to the standard treatment.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05633654
No Compensation